These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 18409526

  • 1. [Inhibitors of xanthine oxidoreductase].
    Okamoto K.
    Nihon Rinsho; 2008 Apr; 66(4):748-53. PubMed ID: 18409526
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
    Terawaki H, Hoshi H, Kazama JJ.
    Clin Exp Nephrol; 2017 Apr; 21(2):356-357. PubMed ID: 28247173
    [No Abstract] [Full Text] [Related]

  • 7. [Febuxostat].
    Wittköpper K, Emons J, El-Armouche A.
    Dtsch Med Wochenschr; 2011 Jun; 136(23):1270-4. PubMed ID: 21607898
    [No Abstract] [Full Text] [Related]

  • 8. Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.
    Ishikawa T, Maeda T, Hashimoto T, Nakagawa T, Ichikawa K, Sato Y, Kanno Y.
    Clin Drug Investig; 2020 Sep; 40(9):847-859. PubMed ID: 32621143
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Febuxostat versus allopurinol for gout.
    Gelber AC.
    N Engl J Med; 2006 Apr 06; 354(14):1532-3; author reply 1532-3. PubMed ID: 16602151
    [No Abstract] [Full Text] [Related]

  • 12. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
    Perez-Ruiz F, Chinchilla SP, Atxotegi J, Urionagüena I, Herrero-Beites AM, Aniel-Quiroga MA.
    Rheumatol Int; 2015 Nov 06; 35(11):1857-61. PubMed ID: 26342297
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Febuxostat: a new treatment for hyperuricaemia in gout.
    Edwards NL.
    Rheumatology (Oxford); 2009 May 06; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
    Prescrire Int; 2009 Apr 06; 18(100):63-5. PubMed ID: 19585722
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.